<DOC>
	<DOC>NCT01356381</DOC>
	<brief_summary>The study will demonstrate the effect of 24 weeks of treatment with vildagliptin compared to placebo on insulin sensitivity in patients with type 2 diabetes mellitus (T2DM) treated with metformin, assessed as glucose Rd (rate of glucose disposal) during a hyperinsulinemic euglycemic clamp.</brief_summary>
	<brief_title>Study to Assess the Effect of 24 Weeks of Treatment With Vildagliptin in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>1. Age in the range of 1870 years. 2. Patients with T2DM, diagnosed at least 6 months prior to Visit 1, who have received metformin for at least 3 months and have been on a stable dose of at least 1000mg daily for a minimum of 4 weeks prior to Visit 1. 3. HbA1c â‰¤ 7.6% at Visit 1. 4. Body mass index (BMI) in the range of 2238kg/m2 inclusive at Visit 1. 1. Pregnant or nursing (lactating) women. 2. Patients with cardiac pacemakers or with metallic implants incompatible with magnetic resonance methodology. 3. Congestive heart failure requiring pharmacologic treatment. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Diabetes mellitus</keyword>
	<keyword>vildagliptin</keyword>
</DOC>